Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study-Reference-Cited by-同舟云学术

Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study

Published:2018-10 Issue:9 Volume:119 Page:1086-1093
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Munster Pamela,Krop Ian E.,LoRusso Patricia,Ma Cynthia,Siegel Barry A.,Shields Anthony F.,Molnár István,Wickham Thomas J.,Reynolds Joseph,Campbell Karen,Hendriks Bart S.,Adiwijaya Bambang S.,Geretti Elena,Moyo Victor,Miller Kathy D.

Funder

Merrimack Pharmaceuticals, Inc.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0235-2.pdf

Reference25 articles.

1. Baselga, J. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109–119 (2012).

2. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).

3. Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783–1791 (2012).